MX2020011733A - Epítopos de células t cooperadoras promiscuos artificiales que facilitan la producción de anticuerpos diana con respuesta inflamatoria de células t limitada. - Google Patents

Epítopos de células t cooperadoras promiscuos artificiales que facilitan la producción de anticuerpos diana con respuesta inflamatoria de células t limitada.

Info

Publication number
MX2020011733A
MX2020011733A MX2020011733A MX2020011733A MX2020011733A MX 2020011733 A MX2020011733 A MX 2020011733A MX 2020011733 A MX2020011733 A MX 2020011733A MX 2020011733 A MX2020011733 A MX 2020011733A MX 2020011733 A MX2020011733 A MX 2020011733A
Authority
MX
Mexico
Prior art keywords
epitopes
cell
limited
antigenic site
promiscuous
Prior art date
Application number
MX2020011733A
Other languages
English (en)
Inventor
Chang Yi Wang
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of MX2020011733A publication Critical patent/MX2020011733A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a nuevos epítopos de células T cooperadoras (epítopos Th) promiscuos y artificiales heterólogos, diseñados para proporcionar una inmunogenicidad óptima de un sitio antigénico diana. Los epítopos Th descritos, cuando se unen covalentemente a un epítopo de células B en una construcción de inmunógeno peptídico, provocan una fuerte respuesta de anticuerpos al epítopo de células B del sitio antigénico diana. Los epítopos Th son inmunosilentes por sí mismos, es decir, pocos, si alguno, de los anticuerpos generados por las construcciones inmunógenas peptídicas se dirigirán hacia el epítopo Th, permitiendo así una respuesta inmune muy enfocada dirigida al sitio antigénico diana. Los epítopos Th promiscuos heterólogos proporcionan inmunógenos peptídicos eficaces y seguros que no generan respuestas inmunitarias inflamatorias, anti-autoinmunitarias, mediadas por células tras la administración.
MX2020011733A 2018-05-04 2019-05-03 Epítopos de células t cooperadoras promiscuos artificiales que facilitan la producción de anticuerpos diana con respuesta inflamatoria de células t limitada. MX2020011733A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862667123P 2018-05-04 2018-05-04
PCT/US2019/030649 WO2019213555A1 (en) 2018-05-04 2019-05-03 Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response

Publications (1)

Publication Number Publication Date
MX2020011733A true MX2020011733A (es) 2021-01-15

Family

ID=68386088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011733A MX2020011733A (es) 2018-05-04 2019-05-03 Epítopos de células t cooperadoras promiscuos artificiales que facilitan la producción de anticuerpos diana con respuesta inflamatoria de células t limitada.

Country Status (12)

Country Link
US (1) US20220023400A1 (es)
EP (1) EP3790581A4 (es)
JP (1) JP2021523127A (es)
KR (1) KR20210010873A (es)
CN (1) CN112218655A (es)
AU (1) AU2019262609A1 (es)
BR (1) BR112020022443A2 (es)
CA (1) CA3099296A1 (es)
MX (1) MX2020011733A (es)
SG (1) SG11202010942WA (es)
TW (1) TWI754817B (es)
WO (1) WO2019213555A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112876570B (zh) * 2021-02-09 2022-07-26 中国农业科学院生物技术研究所 非洲猪瘟病毒疫苗及其制备方法
WO2024015611A2 (en) * 2022-07-14 2024-01-18 Vaxxinity, Inc. Tau peptide immunogen constructs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US20140088020A1 (en) * 1999-08-30 2014-03-27 David S Terman Composition and Methods for Treatment of Cancer
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
AU2003270643A1 (en) * 2002-09-12 2004-04-30 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
JP5863582B2 (ja) * 2012-07-02 2016-02-16 東京エレクトロン株式会社 プラズマ処理装置、及び温度制御方法
JP6502267B2 (ja) * 2013-02-18 2019-04-17 スプリング バンク ファーマシューティカルズ，インコーポレイテッド ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US10450352B2 (en) * 2016-03-23 2019-10-22 Board Of Regents, The University Of Texas System Engineered polypeptides for antigen delivery

Also Published As

Publication number Publication date
CA3099296A1 (en) 2019-11-07
US20220023400A1 (en) 2022-01-27
EP3790581A4 (en) 2022-06-22
TWI754817B (zh) 2022-02-11
KR20210010873A (ko) 2021-01-28
JP2021523127A (ja) 2021-09-02
AU2019262609A1 (en) 2020-12-03
EP3790581A1 (en) 2021-03-17
BR112020022443A2 (pt) 2021-02-09
SG11202010942WA (en) 2020-12-30
TW201946649A (zh) 2019-12-16
CN112218655A (zh) 2021-01-12
WO2019213555A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
MX2021007446A (es) Epítopos artificiales promiscuos de linfocitos t colaboradores como estimuladores inmunes para inmunógenos peptídicos sintéticos.
AU2019293244A8 (en) Personalized cancer vaccine epitope selection
DK1089760T3 (da) Kunstige T-hjælpecelleepitoper som immunstimulatorer for syntetiske peptidimmunogener
MX2020011733A (es) Epítopos de células t cooperadoras promiscuos artificiales que facilitan la producción de anticuerpos diana con respuesta inflamatoria de células t limitada.
EA201992469A1 (ru) Антигенспецифические иммунные эффекторные клетки
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX350230B (es) Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos.
AR104635A1 (es) COMPOSICIONES A BASE DE LISTERIA INMUNOGÉNICA QUE COMPRENDEN FUSIONES DE ANTÍGENO Y ActA TRUNCADA Y MÉTODOS DE USO DE ESTAS
MX2015013235A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
WO2017210579A8 (en) Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
PE20201443A1 (es) Una composicion inmunogenica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparacion de la misma
Xu et al. In vivo assembly of nanoparticles achieved through synergy of structure‐based protein engineering and synthetic DNA generates enhanced adaptive immunity
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
TW201613638A (en) Antibody guided vaccines and methods of use for generation of rapid mature immune responses
WO2019006401A3 (en) LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF
MX2019006104A (es) Conjugados inmunogenicos y uso de los mismos.
EP3715359A1 (en) Cd4 helper t cell epitope fusion peptide and vaccine therewith
EA202090319A1 (ru) Пептидные конъюгаты, способ конъюгации и их использование
EA201400914A1 (ru) Ротавирусная субъединичная вакцина и способы ее получения и применения
MX2019006105A (es) Conjugados de vmen-antigeno y uso de los mismos.
WO2012138754A3 (en) Mycobacterial vaccine vectors and methods of using the same
WO2006091455A3 (en) Molecular scaffolds for hiv-1 immunogens
MX2023005570A (es) Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
MX346878B (es) Nuevos anticuerpos monoclonales contra el receptor dec-205 de celulas dendriticas de pollo.